Gemcitabin helye a lokálisan elôrehaladott vagy metasztatikus húgyhólyagrák kezelésében.

Translated title of the contribution: Role of gemcitabine/cisplatin in the treatment of advanced and metastatic bladder cancer

Research output: Contribution to journalReview article

Abstract

M-VAC combination chemotherapy was considered as the "gold standard" of the treatment of advanced and metastatic bladder cancers. Arrival of gemcitabine or taxanes in the 90s attracted attention since their efficacy was combined with low toxicity profiles. Gemcitabine/cisplatin combination became the most frequently studied treatment modality in the past 3 years. Multicentric, multinational randomized phase-III study indicated that in bladder cancer the gemcitabine/cisplatin combination is equal to M-VAC while in the case of the former the risk to benefit ratio is lower. Accordingly, gemcitabine/cisplatin combination is a safer treatment option in advanced and metastatic bladder cancer and is a real alternative to M-VAC. In the case of patients where cisplatin cannot be administered due to poor renal function, the new drugs with better toxicity profiles provide further treatment options.

Original languageHungarian
Pages (from-to)198-203
Number of pages6
JournalMagyar onkologia
Volume47
Issue number2
Publication statusPublished - 2003

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this